Restricted accessResearch articleFirst published online 2022-06
Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1 R206H Transcript and Inhibit Osteogenic Differentiation
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by episodic heterotopic ossification. The median life span of people with this disorder is ∼40 years, and currently, there is no effective treatment available. More than 95% of cases are caused by a recurrent mutation (c.617G>A; R206H) of Activin A receptor, type I (ACVR1)/Activin receptor-like kinase-2 (ALK2), a bone morphogenetic protein type I receptor. The mutation renders ACVR1 responsive to activin A, which does not activate wild-type ACVR1. Ectopic activation of ACVR1R206H by activin A induces heterotopic ossification. Since ACVR1R206H is a hyperactive receptor, a promising therapeutic strategy is to decrease the activity of mutated ACVR1. To accomplish this goal, we developed locked nucleic acid (LNA) gapmers. These are short DNA oligonucleotides with LNA modification at both ends. They induce targeted mRNA degradation and specific knockdown of gene expression. We demonstrated that some of these gapmers efficiently knocked down ACVR1R206H expression at RNA levels, while ACVR1WT was mostly unaffected in human FOP fibroblasts. Also, the gapmers suppressed osteogenic differentiation induced by ACVR1R206H and activin A. These gapmers may be promising drug candidates for FOP. This novel strategy will also pave the way for antisense-mediated therapy of other autosomal dominant disorders.
Get full access to this article
View all access options for this article.
References
1.
PignoloRJ, ShoreEM and Kaplan.FS (2011). Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis, 6:80.
2.
ShoreEM, XuM, FeldmanGJ, FenstermacherDA, ChoTJ, ChoiIH, ConnorJM, DelaiP, GlaserDL, et al. (2006). A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet, 38:525–527.
3.
HuningI and Gillessen-KaesbachG. (2014). Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation. Mol Syndromol, 5:201–211.
4.
HatsellSJ, IdoneV, WolkenDM, HuangL, KimHJ, WangL, WenX, NannuruKC, JimenezJ, et al. (2015). ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med, 7:303ra137.
5.
HinoK, IkeyaM, HorigomeK, MatsumotoY, EbiseH, NishioM, SekiguchiK, ShibataM, NagataS, et al. (2015). Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci U S A, 112:15438–15443.
6.
DeyD, BagarovaJ, HatsellSJ, ArmstrongKA, HuangL, ErmannJ, VonnerAJ, ShenY, MohedasAH, et al. (2016). Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification. Sci Transl Med, 8:366ra163.
ChakkalakalSA, UchibeK, ConventeMR, ZhangD, EconomidesAN, KaplanFS, PacificiM, IwamotoM and ShoreEM. (2016). Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human acVR1(R206H) fibrodysplasia ossificans progressiva (FOP) mutation. J Bone Miner Res, 31:1666–1675.
9.
HinoK, HorigomeK, NishioM, KomuraS, NagataS, ZhaoC, JinY, KawakamiK, YamadaY, et al. (2017). Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva. J Clin Invest, 127:3339–3352.
10.
HinoK, ZhaoC, HorigomeK, NishioM, OkanishiY, NagataS, KomuraS, YamadaY, ToguchidaJ, et al. (2018). An mTOR signaling modulator suppressed heterotopic ossification of fibrodysplasia ossificans progressiva. Stem Cell Rep, 11:1106–1119.
11.
VanhoutteF, LiangS, RuddyM, ZhaoA, DreweryT, WangY, DelGizziR, Forleo-NetoE, RajadhyakshaM, et al. (2020). Pharmacokinetics and pharmacodynamics of garetosmab (Anti-Activin A): results from a first-in-human phase 1 study. J Clin Pharmacol, 60:1424–1431.
12.
GuZ, ReynoldsEM, SongJ, LeiH, FeijenA, YuL, HeW, MacLaughlinDT, van den Eijnden-van RaaijJ, et al. (1999). The type I serine/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo. Development, 126:2551–2561.
13.
MishinaY, CrombieR, BradleyA and BehringerRR. (1999). Multiple roles for activin-like kinase-2 signaling during mouse embryogenesis. Dev Biol, 213:314–326.
14.
DudasM, SridurongritS, NagyA, OkazakiK and KaartinenV (2004). Craniofacial defects in mice lacking BMP type I receptor Alk2 in neural crest cells. Mech Dev, 121:173–182.
15.
Lees-ShepardJB, NicholasSE, StoesselSJ, DevarakondaPM, SchneiderMJ, YamamotoM and GoldhamerDJ (2018). Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity. Elife, 7:e40814.
16.
KaplanJ, KaplanFS and ShoreEM (2012). Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting. Gene Ther, 19:786–790.
17.
TakahashiM, KatagiriT, FuruyaH and HohjohH. (2012). Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva. Gene Ther, 19:781–785.
18.
SkotteNH, SouthwellAL, OstergaardME, CarrollJB, WarbySC, DotyCN, PetoukhovE, VaidK, KordasiewiczH, et al. (2014). Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One, 9:e107434.
19.
SouthwellAL, SkotteNH, KordasiewiczHB, OstergaardME, WattAT, CarrollJB, DotyCN, VillanuevaEB, PetoukhovE, et al. (2014). In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther, 22:2093–2106.
20.
SouthwellAL, KordasiewiczHB, LangbehnD, SkotteNH, ParsonsMP, VillanuevaEB, CaronNS, OstergaardME, AndersonLM, et al. (2018) Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. Sci Transl Med, 10:eaar3959.
21.
ScolesDR, MinikelEV and Pulst.SM (2019). Antisense oligonucleotides: a primer. Neurol Genet, 5:e323.
22.
WahlestedtC, SalmiP, GoodL, KelaJ, JohnssonT, HokfeltT, BrobergerC, PorrecaF, LaiJ, et al. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A, 97:5633–5638.
23.
MaruyamaR, TouznikA and Yokota.T (2018). Evaluation of exon inclusion induced by splice switching antisense oligonucleotides in SMA patient fibroblasts. J Vis Exp, 135:57530.
24.
FukudaT, KanomataK, NojimaJ, KokabuS, AkitaM, IkebuchiK, JimiE, KomoriT, MarukiY, et al. (2008). A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem Biophys Res Commun, 377:905–909.
25.
ObikaS, NanbuD, HariY, MorioK, InY, IshidaT and ImanishiT. (1997). Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C-3,-endo sugar puckering. Tetrahedron Lett, 38:8735–8738.
26.
SinghSK, NielsenP, KoshkinAA and Wengel.J (1998). LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition. Chem Commun DOI: https://doi.org/10.1039/A708608C.
27.
CrookeST, WangS, VickersTA, ShenW and LiangXH. (2017). Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol, 35:230–237.
28.
FukudaT, KohdaM, KanomataK, NojimaJ, NakamuraA, KamizonoJ, NoguchiY, IwakiriK, KondoT, et al. (2009). Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J Biol Chem, 284:7149–7156.
29.
SongGA, KimHJ, WooKM, BaekJH, KimGS, ChoiJY and RyooHM. (2010). Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J Biol Chem, 285:22542–22553.
30.
ShiS, CaiJ, de GorterDJ, Sanchez-DuffhuesG, KemaladewiDU, HoogaarsWM, Aartsma-RusA, t HoenPA and ten DijkeP. (2013) Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva. PLoS One, 8:e69096.
31.
AsleshT and YokotaT. (2020). Development of antisense oligonucleotide gapmers for the treatment of dyslipidemia and lipodystrophy. Methods Mol Biol, 2176:69–85.
32.
MahfouzM, MaruyamaR and YokotaT. (2020). Inotersen for the treatment of hereditary transthyretin amyloidosis. Methods Mol Biol, 2176:87–98.
33.
ChanL and YokotaT. (2020). Development and clinical applications of antisense oligonucleotide gapmers. Methods Mol Biol, 2176:21–47.
34.
RupaimooleR and SlackFJ. (2017). MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov, 16:203–222.
35.
CarrollJB, WarbySC, SouthwellAL, DotyCN, GreenleeS, SkotteN, HungG, BennettCF, FreierSM, et al. (2011). Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther, 19:2178–2185.
36.
PfeifferN, VoykovB, RenieriG, BellK, RichterP, WeigelM, ThiemeH, WilhelmB, LorenzK, et al. (2017). First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-beta2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery. PLoS One, 12:e0188899.
37.
Frazier KS. (2015). Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. Toxicol Pathol, 43:78–89.
38.
ShenW, De HoyosCL, MigawaMT, VickersTA, SunH, LowA, BellTA, III, RahdarM, MukhopadhyayS, et al. (2019). Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol, 37:640–650.
39.
KhvorovaA and WattsJK. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol, 35:238–248.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
